Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Study ID
- NCT00384826
- Phase
- PHASE2
- Status
- Completed
Conditions
- Adenocarcinoma, Bronchiolo-Alveolar
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- erlotinib — DRUGErlotinib 150 mg/day (until progression)
- paclitaxel + carboplatine — DRUGPaclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
Study Details
To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.
Key Dates
- First listed
- Oct 6, 2006
- Start date
- Sep 30, 2006
- Status verified
- Feb 2015
- Primary completion
- Feb 28, 2014
- Completion
- Feb 28, 2014
Study Design
- Enrollment
- 133 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
- Experimental: 2
Primary Outcome Measure
16-week Disease Control Rate [ Time Frame: 4-week ]